Clinical Trial Update: ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response [Phase 2]

View source ↗

Summary

Phase 2 ACP-211 monotherapy for major depressive disorder is currently recruiting, including treatment-resistant cases. The sponsor is ACADIA Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• ACP-211

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | Phase 2 | Status: RECRUITING